The adding of the programmed death-ligand 1 (PDL1) inhibitor atezolizumab into platinum-based frontline chemotherapy of extensive stage SCLC (ES-SCLC) has improved median overall survival from 10.3 months to 12.3 months, with only 34.0% of patients remaining alive at 18 months [5]. The gene discussed is CD274; the disease is small cell lung carcinoma.